Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Zakattack who wrote (13975)	5/4/1998 12:20:00 PM
From: Bill Monahan	Respond to of 34592

SNKI P/E of 4 and up 28% today

To: Zakattack who wrote (13975)	5/4/1998 12:21:00 PM
From: Eski	Respond to of 34592

From dayinvestor.com "There are a handful of other companies currently working on their own anti-angiogenesis drugs which are in varying stages of development and may benefit from the attention ENMD will undoubtedly receive this AM. These include SUGN, IMCL, BBIOY, BLSI, MAGN among others. Of these MAGN seems a likely candidate -from their release of 31 March regarding their product Squalamine" Squalamine has been shown to be a new type of inhibitor of angiogenesis. Angiogenesis is the process of budding and growth of new blood vessels from existing blood vessels under the stimulus of a variety of growth factors. Squalamine inhibits the growth of tumor-induced new blood vessels in animal systems, and also reduces the spread of tumor metastases. Phase I clinical testing of squalamine is being conducted at the Cancer Therapy and Research Center " ESKI